Experienced in Heart Attack

Lixia Yang

Kunming, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Heart Attack
Kunming, CN 
OverviewLocationsClinical Research

Overview

Lixia Yang practices in Kunming, China. Yang is rated as an Experienced expert by MediFind in the treatment of Heart Attack. Their top areas of expertise are Coronary Artery Fistula, Heart Attack, Coronary Heart Disease, Percutaneous Coronary Intervention (PCI), and Angioplasty.

Their clinical research consists of co-authoring 28 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 9 articles in the study of Heart Attack.

Locations

Kunming, China
Other Locations
650032, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
Enrollment Status: Recruiting
Publish Date: February 01, 2024
Intervention Type: Drug
Study Drug: rhNRG-1
Study Phase: Phase 3
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Enrollment Status: Terminated
Publish Date: December 21, 2017
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

28 Total Publications

Correction: Global burden of atrial fibrillation and atrial flutter due to high alcohol use from 1990 to 2021: estimates from the global burden of disease study 2021.
Correction: Global burden of atrial fibrillation and atrial flutter due to high alcohol use from 1990 to 2021: estimates from the global burden of disease study 2021.
Journal: BMC cardiovascular disorders
Published: August 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yang's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile